Steven Lydeamore
Vermögen: 79 760 $ am 31.07.2026
Vermögen: 79 760 $ am 31.07.2026
Steven Lydeamore currently works at Immuron Ltd., as Chief Executive Officer from 2022, Australian Institute of Co. Directors, as Member, and CPA Australia Ltd., as Member.
Mr. Lydeamore also formerly worked at Anatara Lifesciences Ltd., as Chief Executive Officer from 2018 to 2022, Bionomics Ltd., as Chief Financial Officer from 2017 to 2018, Apotex, Inc., as President-Apobiologix from 2015 to 2016, Licensing Executives Society USA & Canada, Inc., as Member, and Apobiologix, Inc., as President.
Mr. Lydeamore received his undergraduate degree in 1990 from Deakin University and Masters Business Admin degree in 1999 from RMIT University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMURON LIMITED 0.98% | 18.03.2026 | 3’155’047 ( 0.98% ) | 79 760 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMURON LIMITED | Vorstandsvorsitzender | 27.06.2022 |
CPA Australia Ltd.
CPA Australia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides education, training, technical support and advocacy for the members | Corporate Officer/Principal | - |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Corporate Officer/Principal | - |
| Unternehmen | Position | Ende |
|---|---|---|
| ANATARA LIFESCIENCES LTD | Vorstandsvorsitzender | 26.06.2022 |
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Finanzdirektor/CFO | 23.11.2018 |
Apotex, Inc.
Apotex, Inc. Pharmaceuticals: GenericHealth Technology Manufactures generic medicines | Corporate Officer/Principal | 01.04.2016 |
Licensing Executives Society USA & Canada, Inc.
Licensing Executives Society USA & Canada, Inc. Miscellaneous Commercial ServicesCommercial Services Operates association for intellectual property, technology, and business development professionals | Corporate Officer/Principal | - |
Apobiologix, Inc.
Apobiologix, Inc. BiotechnologyHealth Technology Develops and distributes bio similar therapies | Präsident | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Health Technology |
Apotex, Inc.
Apotex, Inc. Pharmaceuticals: GenericHealth Technology Manufactures generic medicines | Health Technology |
Immuron Ltd.
Immuron Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Deakin University
Deakin University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RMIT University
RMIT University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Commercial Services |
CPA Australia Ltd.
CPA Australia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides education, training, technical support and advocacy for the members | Commercial Services |
Licensing Executives Society USA & Canada, Inc.
Licensing Executives Society USA & Canada, Inc. Miscellaneous Commercial ServicesCommercial Services Operates association for intellectual property, technology, and business development professionals | Commercial Services |
Anatara Lifesciences Ltd.
Anatara Lifesciences Ltd. Pharmaceuticals: MajorHealth Technology Develops non-antibiotic oral solutions for gastrointestinal diseases in animals and humans | Health Technology |
Apobiologix, Inc.
Apobiologix, Inc. BiotechnologyHealth Technology Develops and distributes bio similar therapies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen